agonistic antibodies

New coverage from Technology Networks examines efforts to design improved agonistic antibodies, drugs that activate immune-cell receptors to help the body attack tumours. The piece outlines how engineering strategies aim to enhance their potency and safety for cancer immunotherapy, a fast-growing field where several agonistic antibody candidates have struggled to show clinical benefit so far.